These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 31980175)
1. BRAF Feng L; Li J; Bu X; Zuo Y; Shen L; Qu X Biochem Biophys Res Commun; 2020 Mar; 524(1):28-35. PubMed ID: 31980175 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of USP14 enhances anti-tumor effect in vemurafenib-resistant melanoma by regulation of Skp2. Wu T; Li C; Zhou C; Niu X; Li G; Zhou Y; Gu X; Cui H Cell Biol Toxicol; 2023 Oct; 39(5):2381-2399. PubMed ID: 35648318 [TBL] [Abstract][Full Text] [Related]
3. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428 [TBL] [Abstract][Full Text] [Related]
4. Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma. Park BS; Jeon H; Kim Y; Kwon H; Choi GE; Chi SG; Park HM; Lee H; Kim T Mol Cancer; 2024 Jul; 23(1):136. PubMed ID: 38965534 [TBL] [Abstract][Full Text] [Related]
5. Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463 [No Abstract] [Full Text] [Related]
6. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells. Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432 [TBL] [Abstract][Full Text] [Related]
7. Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting. Carroll MJ; Parent CR; Page D; Kreeger PK BMC Cancer; 2019 Oct; 19(1):1025. PubMed ID: 31672130 [TBL] [Abstract][Full Text] [Related]
8. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells. Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656 [TBL] [Abstract][Full Text] [Related]
9. HI-511 overcomes melanoma drug resistance Chang X; Zhang T; Wang Q; Rathore MG; Reddy K; Chen H; Shin SH; Ma WY; Bode AM; Dong Z Theranostics; 2020; 10(21):9721-9740. PubMed ID: 32863956 [No Abstract] [Full Text] [Related]
10. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467 [TBL] [Abstract][Full Text] [Related]
11. Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma. Jalili A; Wagner C; Pashenkov M; Pathria G; Mertz KD; Widlund HR; Lupien M; Brunet JP; Golub TR; Stingl G; Fisher DE; Ramaswamy S; Wagner SN J Natl Cancer Inst; 2012 Nov; 104(21):1673-9. PubMed ID: 22997239 [TBL] [Abstract][Full Text] [Related]
12. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Shi H; Moriceau G; Kong X; Koya RC; Nazarian R; Pupo GM; Bacchiocchi A; Dahlman KB; Chmielowski B; Sosman JA; Halaban R; Kefford RF; Long GV; Ribas A; Lo RS Cancer Discov; 2012 May; 2(5):414-24. PubMed ID: 22588879 [TBL] [Abstract][Full Text] [Related]
14. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. Zhuang D; Mannava S; Grachtchouk V; Tang WH; Patil S; Wawrzyniak JA; Berman AE; Giordano TJ; Prochownik EV; Soengas MS; Nikiforov MA Oncogene; 2008 Nov; 27(52):6623-34. PubMed ID: 18679422 [TBL] [Abstract][Full Text] [Related]
15. BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma. Walter L; Heinzerling L Anticancer Res; 2018 Mar; 38(3):1335-1341. PubMed ID: 29491057 [TBL] [Abstract][Full Text] [Related]
16. EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile. Zhang J; Lu B; Liu D; Shen R; Yan Y; Yang L; Zhang M; Zhang L; Cao G; Cao H; Fu B; Gong A; Sun Q; Wan H; Zhang L; Tao W; Cao J Cancer Biol Ther; 2016; 17(2):199-207. PubMed ID: 26810733 [TBL] [Abstract][Full Text] [Related]
17. Targeting CDC7 sensitizes resistance melanoma cells to BRAF Gad SA; Ali HEA; Gaballa R; Abdelsalam RM; Zerfaoui M; Ali HI; Salama SH; Kenawy SA; Kandil E; Abd Elmageed ZY Sci Rep; 2019 Oct; 9(1):14197. PubMed ID: 31578454 [TBL] [Abstract][Full Text] [Related]
18. Transcripts 202 and 205 of IL-6 confer resistance to Vemurafenib by reactivating the MAPK pathway in BRAF(V600E) mutant melanoma cells. Zhao K; Lu Y; Chen Y; Cheng J; Zhang W Exp Cell Res; 2020 May; 390(2):111942. PubMed ID: 32173467 [TBL] [Abstract][Full Text] [Related]
19. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Parmenter TJ; Kleinschmidt M; Kinross KM; Bond ST; Li J; Kaadige MR; Rao A; Sheppard KE; Hugo W; Pupo GM; Pearson RB; McGee SL; Long GV; Scolyer RA; Rizos H; Lo RS; Cullinane C; Ayer DE; Ribas A; Johnstone RW; Hicks RJ; McArthur GA Cancer Discov; 2014 Apr; 4(4):423-33. PubMed ID: 24469106 [TBL] [Abstract][Full Text] [Related]
20. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma. Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]